Skip to content

Intermitterende sacrale neuromodulatie bij idiopathische overactieve blaas.

Intermittent sacral neuromodulation for treatment of idiopathic overactive bladder in women.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON23224
Enrollment
16
Registered
2014-09-08
Start date
2014-06-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder, sacral neuromodulation

Interventions

In all patients the implantable neurostimulator will be automatically turned off for 18 hours a day.

Sponsors

Erasmus Medical Center Rotterdam, Department Urology.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients who: • have given written informed consent • have sufficient knowledge of the Dutch language to understand the informed consent form and to complete the questionnaires • are female and are at least 18 years of age • have had subjective successful treatment for at least 6 months through sacral neuromodulation using InterStim for OAB • have had at least three months of anticholinergic treatment without result or who had to stop anticholinergic treatment because of adverse side effects before implantation of the neuromodulator • currently do not use anticholinergic or other medical treatment for idiopathic OAB • have had their last intravesical Botox treatment at least 12 months ago

Exclusion criteria

Exclusion criteria: Patients who: • have a neuropathic bladder • have a symptomatic urinary tract infection • have an indwelling catheter or who apply clean intermittent catheterization • have an implantable neurostimulator of which the estimated service life of the battery is less than 1 year at the moment of inclusion in the study • have had radiation therapy of the pelvis • have had bladder cancer

Design outcomes

Secondary

MeasureTime frame
Derived from voiding diaries - Urinary frequency per 24 hours - Number of pads used - Average volume per voiding. Change from baseline to intermittent stimulation Difference between intermittent and continuous stimulation. Standard scores from questionnaires (IIQ-7, UDI-6, PFDI-20, PFIQ-7, PISQ, EuroQOL-5, FICI, FIQL) Change from baseline to intermittent stimulation. Difference between intermittent and continuous stimulation.

Primary

MeasureTime frame
Incontinence episodes per day compared to baseline, derived from voiding diaries.

Contacts

Public ContactL.A. Hoen, 't
l.thoen@erasmusmc.nl010 - 703 65 59

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)